Operator of a digital medicine company intended to provide insights on laboratory test results that are understandable to patients. The company fosters the interactions between laboratories, health professionals and patients and goes beyond results in patient care through the use of new technologies and artificial intelligence, enabling medical professionals to easily interpret and diagnose in a personalized and effective way.
Ganymed Robotics SAS, a medical device company, focuses on the development of robotics technologies for orthopedic surgeons. It develops a therapeutic device to enhance surgical precision in knee replacement surgery. The company was incorporated in 2018 and is based in Paris, France.
Ermium Therapeutics is a biotechnology company based in Paris, France, focused on developing innovative therapies for auto-immune and inflammatory diseases. Founded in June 2019, the company centers its research on CXCR4, identified as a master regulator of inflammation, which allows for the control of interferons by plasmacytoid dendritic cells. Ermium Therapeutics has secured an exclusive worldwide license for its intellectual property from CNRS and University Paris Descartes, facilitated by Erganeo, which has aided in advancing the project within an academic environment. The company has also been recognized for its innovative approach, having won the innovation i-Lab 2019 award from the French Ministry of Research and Higher Education.
Charles helps men regain control over their daily health concerns by starting with their personal health. The company was founded in Paris, Ile-de-France, France in 2019.
DAMAE Medical SAS, founded in 2014 and based in Paris, France, specializes in developing advanced medical imaging technologies for dermatology. The company's flagship product, OCTAV, employs innovative optical imaging techniques to provide in vivo, cellular-level images of skin tissues, offering insights similar to traditional histology without requiring tissue excision or processing. This non-invasive approach enables dermatologists to assess the malignancy of skin tumors with precision and efficiency through simple contact with the skin's surface. By leveraging bio-photonics, DAMAE Medical aims to enhance diagnostic capabilities in dermatology, facilitating timely and accurate evaluations of skin cancer.
Corteria Pharmaceuticals is a biotechnology company dedicated to developing innovative therapies for heart failure subpopulations, particularly those experiencing worsening and acute decompensated heart failure. The company focuses on addressing unmet medical needs in this area and aims to provide effective treatments that enhance understanding of the underlying disease biology. Additionally, Corteria's research extends to related conditions such as sarcopenia and obesity, positioning the company to make a significant impact on the management of these interconnected health issues.
PathoQuest SAS is a biotechnology company based in Paris, France, focused on advancing pathogen detection through a metagenomics approach. Founded in 2010 as a spin-off from Institut Pasteur, the company utilizes proprietary next-generation sequencing (NGS) technology to provide actionable reports for clinicians, biologists, and biopharmaceutical professionals. PathoQuest’s offerings include the iDTECTTM Dx Blood test for pathogen identification and a comprehensive database that enhances diagnostic accuracy. Additionally, the company provides Viral Safety testing services specifically designed for biopharmaceutical firms, which has quickly established a revenue stream from major industry players. The integration of advanced sample preparation and cloud-based bioinformatics enables improved detection capabilities across various biological samples, allowing healthcare professionals to address the limitations of traditional infectious agent detection methods.
Developer of a tele-expertise platform designed to facilitate phone-based medical verification for patients eligible for health insurance facilities. The company's platform allows medical institutions or private physicians to secure and value informal opinions, strengthen the links between first and second recourse, centralize and promote requests from correspondents, and discover and contact doctors and organizations, enabling clients to improve, secure, and enhance the opinions exchanged and automate administrative tasks.
Arkhn is a platform specialist in healthcare data interoperability. Arkhn tackles the issue of accessing healthcare data.
Step Pharma, founded in 2014 and based in Paris, France, is a biopharmaceutical company specializing in the development of novel small molecule therapeutics for immunosuppressive therapies aimed at treating autoimmune diseases. A spin-off of the Imagine Institute, Step Pharma emerged from research led by Professor Alain Fischer on genetic immunodeficiencies. The company collaborates with Sygnature Discovery, a prominent drug discovery services provider, and Kurma Partners, an investor focused on healthcare and biotechnology in Europe. Its proprietary therapeutics utilize a unique class of oral nucleotide synthesis inhibitors that specifically target cytidine triphosphate synthase 1 (CTPS1). This approach allows for the selective modulation of immune cell populations, such as T and B cells, enhancing treatment efficacy and improving therapeutic outcomes for patients with autoimmune disorders.
Poppins is a developer of digital therapeutic technology aimed at enhancing cognitive function in children with learning disorders. The company creates interactive musical games that integrate neurologic music therapy methods to address conditions such as dyslexia, dysphasia, and dyspraxia. These games focus on improving essential skills like concentration, motor skills, and memory through engaging activities that can be performed at home. By leveraging data science and advanced technologies, Poppins interprets learning, language, and motor performance to generate a cognitive score, facilitating personalized treatment plans. The company's mission is to provide accessible digital solutions for children facing learning challenges, ultimately aiming to improve their reading abilities and memory retention while supporting speech therapy.
Operator of a biotechnological therapeutic platform intended to provide financial assistance and operational excellence to early-stage projects. The company's platform identifies, selects, and incubates early-stage biotechnology projects that focus on selected therapeutic areas such as rare diseases, neurological disorders, oncology, and immunology, enabling startups to further develop their medicinal and drug research process.
Corlieve Therapeutics SAS, a biotechnology company, develops therapeutic options to patients with severe neurological disorders. Its lead project is targeting aberrantly expressed kainate receptors in the hippocampus of patients with temporal lobe epilepsy (TLE) using a gene therapy approach. The company’s program employs a novel AAV gene therapy approach for the treatment of refractory TLE and is based on science from INSERM, CNRS, Aix Marseille University, and the University of Bordeaux. The company was incorporated in 2019 and is based in Paris, France.
Cardiologs Technologies SAS is a medical technology company based in Paris, France, founded in 2014. It specializes in the development of a cloud-based platform for electrocardiogram (ECG) analysis that enhances the management of cardiac patients. The Cardiologs ECG Analysis Platform leverages medical-grade artificial intelligence and deep learning technology to assist physicians in screening for conditions such as atrial fibrillation and other arrhythmias. The platform analyzes long-term ambulatory ECG recordings and recognizes patterns in digital ECG signals, providing clinicians with critical insights for interpreting heart disorders. Cardiologs aims to democratize expert cardiac care by making advanced diagnostics accessible to healthcare practitioners globally. Its extensive database of over 1,450,000 recordings, supported by clinical publications, underpins its commitment to delivering high-quality cardiac diagnostics.
FeetMe SAS is a medical technology company based in Paris, France, specializing in the development of innovative insoles designed for real-time foot pressure mapping, particularly for diabetic patients. Founded in 2013, the company's insoles incorporate pressure sensors that create detailed pressure maps, alerting patients and healthcare providers to potential changes in plantar pressure. FeetMe's products include connected insoles and mobile software that assess gait and mobility parameters in real-life settings, utilizing advanced algorithms and wireless technology. These solutions are marketed to pharmaceutical companies for clinical trials, as well as to hospitals and rehabilitation centers for mobility assessments and gait training. Ultimately, FeetMe aims to address the growing global issue of mobility disorders, facilitating better therapeutic evaluations and rehabilitation outcomes for patients.
Ermium Therapeutics is a biotechnology company based in Paris, France, focused on developing innovative therapies for auto-immune and inflammatory diseases. Founded in June 2019, the company centers its research on CXCR4, identified as a master regulator of inflammation, which allows for the control of interferons by plasmacytoid dendritic cells. Ermium Therapeutics has secured an exclusive worldwide license for its intellectual property from CNRS and University Paris Descartes, facilitated by Erganeo, which has aided in advancing the project within an academic environment. The company has also been recognized for its innovative approach, having won the innovation i-Lab 2019 award from the French Ministry of Research and Higher Education.
PathoQuest SAS is a biotechnology company based in Paris, France, focused on advancing pathogen detection through a metagenomics approach. Founded in 2010 as a spin-off from Institut Pasteur, the company utilizes proprietary next-generation sequencing (NGS) technology to provide actionable reports for clinicians, biologists, and biopharmaceutical professionals. PathoQuest’s offerings include the iDTECTTM Dx Blood test for pathogen identification and a comprehensive database that enhances diagnostic accuracy. Additionally, the company provides Viral Safety testing services specifically designed for biopharmaceutical firms, which has quickly established a revenue stream from major industry players. The integration of advanced sample preparation and cloud-based bioinformatics enables improved detection capabilities across various biological samples, allowing healthcare professionals to address the limitations of traditional infectious agent detection methods.
PathoQuest SAS is a biotechnology company based in Paris, France, focused on advancing pathogen detection through a metagenomics approach. Founded in 2010 as a spin-off from Institut Pasteur, the company utilizes proprietary next-generation sequencing (NGS) technology to provide actionable reports for clinicians, biologists, and biopharmaceutical professionals. PathoQuest’s offerings include the iDTECTTM Dx Blood test for pathogen identification and a comprehensive database that enhances diagnostic accuracy. Additionally, the company provides Viral Safety testing services specifically designed for biopharmaceutical firms, which has quickly established a revenue stream from major industry players. The integration of advanced sample preparation and cloud-based bioinformatics enables improved detection capabilities across various biological samples, allowing healthcare professionals to address the limitations of traditional infectious agent detection methods.
Step Pharma, founded in 2014 and based in Paris, France, is a biopharmaceutical company specializing in the development of novel small molecule therapeutics for immunosuppressive therapies aimed at treating autoimmune diseases. A spin-off of the Imagine Institute, Step Pharma emerged from research led by Professor Alain Fischer on genetic immunodeficiencies. The company collaborates with Sygnature Discovery, a prominent drug discovery services provider, and Kurma Partners, an investor focused on healthcare and biotechnology in Europe. Its proprietary therapeutics utilize a unique class of oral nucleotide synthesis inhibitors that specifically target cytidine triphosphate synthase 1 (CTPS1). This approach allows for the selective modulation of immune cell populations, such as T and B cells, enhancing treatment efficacy and improving therapeutic outcomes for patients with autoimmune disorders.
Horama SAS is a biotechnology company based in Paris, France, established in 2014. It specializes in developing gene therapy products aimed at treating rare ophthalmic diseases, particularly targeting inherited retinal dystrophies and retinopathies. By utilizing recombinant adeno-associated viral vectors, Horama's therapies aim to deliver a functional copy of mutated genes to affected retinal cells. This approach seeks to restore normal cell function, prevent further deterioration of vision, and ultimately improve or restore visual capabilities for patients. The company is positioning itself as a significant player in the ophthalmic gene therapy sector, with the goal of enhancing patient autonomy while also contributing to reduced healthcare costs.
Cardiologs Technologies SAS is a medical technology company based in Paris, France, founded in 2014. It specializes in the development of a cloud-based platform for electrocardiogram (ECG) analysis that enhances the management of cardiac patients. The Cardiologs ECG Analysis Platform leverages medical-grade artificial intelligence and deep learning technology to assist physicians in screening for conditions such as atrial fibrillation and other arrhythmias. The platform analyzes long-term ambulatory ECG recordings and recognizes patterns in digital ECG signals, providing clinicians with critical insights for interpreting heart disorders. Cardiologs aims to democratize expert cardiac care by making advanced diagnostics accessible to healthcare practitioners globally. Its extensive database of over 1,450,000 recordings, supported by clinical publications, underpins its commitment to delivering high-quality cardiac diagnostics.
FeetMe SAS is a medical technology company based in Paris, France, specializing in the development of innovative insoles designed for real-time foot pressure mapping, particularly for diabetic patients. Founded in 2013, the company's insoles incorporate pressure sensors that create detailed pressure maps, alerting patients and healthcare providers to potential changes in plantar pressure. FeetMe's products include connected insoles and mobile software that assess gait and mobility parameters in real-life settings, utilizing advanced algorithms and wireless technology. These solutions are marketed to pharmaceutical companies for clinical trials, as well as to hospitals and rehabilitation centers for mobility assessments and gait training. Ultimately, FeetMe aims to address the growing global issue of mobility disorders, facilitating better therapeutic evaluations and rehabilitation outcomes for patients.
Vivet Therapeutics is dedicated to developing innovative gene therapy treatments for orphan diseases.
Vivet Therapeutics is focused on optimizing gene therapy through a partnership with the Fundacion para la Investigacion Medica Aplicada (FIMA) at the Centro de Investigación Medica Aplicada (CIMA, Universidad de Navarra) to develop new AAV vectors specifically targeting the liver and generating new technologies to optimize gene delivery and long term expression.
DAMAE Medical SAS, founded in 2014 and based in Paris, France, specializes in developing advanced medical imaging technologies for dermatology. The company's flagship product, OCTAV, employs innovative optical imaging techniques to provide in vivo, cellular-level images of skin tissues, offering insights similar to traditional histology without requiring tissue excision or processing. This non-invasive approach enables dermatologists to assess the malignancy of skin tumors with precision and efficiency through simple contact with the skin's surface. By leveraging bio-photonics, DAMAE Medical aims to enhance diagnostic capabilities in dermatology, facilitating timely and accurate evaluations of skin cancer.
BioSerenity souhaite aider la communauté scientifique à mieux comprendre l'épilepsie pour mieux la soigner. Une fois anonymisées et privées de tout lien avec le patient, les données recueillies seront mise à disposition des chercheurs de l'Institut du Cerveau et de la Moelle épinière (ICM). C'est un pas décisif pour faire avancer la recherche sur l'épilepsie et améliorer le futur du diagnostic
PathoQuest SAS is a biotechnology company based in Paris, France, focused on advancing pathogen detection through a metagenomics approach. Founded in 2010 as a spin-off from Institut Pasteur, the company utilizes proprietary next-generation sequencing (NGS) technology to provide actionable reports for clinicians, biologists, and biopharmaceutical professionals. PathoQuest’s offerings include the iDTECTTM Dx Blood test for pathogen identification and a comprehensive database that enhances diagnostic accuracy. Additionally, the company provides Viral Safety testing services specifically designed for biopharmaceutical firms, which has quickly established a revenue stream from major industry players. The integration of advanced sample preparation and cloud-based bioinformatics enables improved detection capabilities across various biological samples, allowing healthcare professionals to address the limitations of traditional infectious agent detection methods.
Step Pharma, founded in 2014 and based in Paris, France, is a biopharmaceutical company specializing in the development of novel small molecule therapeutics for immunosuppressive therapies aimed at treating autoimmune diseases. A spin-off of the Imagine Institute, Step Pharma emerged from research led by Professor Alain Fischer on genetic immunodeficiencies. The company collaborates with Sygnature Discovery, a prominent drug discovery services provider, and Kurma Partners, an investor focused on healthcare and biotechnology in Europe. Its proprietary therapeutics utilize a unique class of oral nucleotide synthesis inhibitors that specifically target cytidine triphosphate synthase 1 (CTPS1). This approach allows for the selective modulation of immune cell populations, such as T and B cells, enhancing treatment efficacy and improving therapeutic outcomes for patients with autoimmune disorders.
PathoQuest SAS is a biotechnology company based in Paris, France, focused on advancing pathogen detection through a metagenomics approach. Founded in 2010 as a spin-off from Institut Pasteur, the company utilizes proprietary next-generation sequencing (NGS) technology to provide actionable reports for clinicians, biologists, and biopharmaceutical professionals. PathoQuest’s offerings include the iDTECTTM Dx Blood test for pathogen identification and a comprehensive database that enhances diagnostic accuracy. Additionally, the company provides Viral Safety testing services specifically designed for biopharmaceutical firms, which has quickly established a revenue stream from major industry players. The integration of advanced sample preparation and cloud-based bioinformatics enables improved detection capabilities across various biological samples, allowing healthcare professionals to address the limitations of traditional infectious agent detection methods.
PathoQuest SAS is a biotechnology company based in Paris, France, focused on advancing pathogen detection through a metagenomics approach. Founded in 2010 as a spin-off from Institut Pasteur, the company utilizes proprietary next-generation sequencing (NGS) technology to provide actionable reports for clinicians, biologists, and biopharmaceutical professionals. PathoQuest’s offerings include the iDTECTTM Dx Blood test for pathogen identification and a comprehensive database that enhances diagnostic accuracy. Additionally, the company provides Viral Safety testing services specifically designed for biopharmaceutical firms, which has quickly established a revenue stream from major industry players. The integration of advanced sample preparation and cloud-based bioinformatics enables improved detection capabilities across various biological samples, allowing healthcare professionals to address the limitations of traditional infectious agent detection methods.
Meiogenix SAS is a biotechnology company based in Paris, France, that specializes in developing breeding and genomic technologies aimed at unlocking the unexplored genetic diversity of organisms. Established in 2010, Meiogenix offers innovative solutions such as SpiX technology, which enhances homologous recombination in specific regions of the genome, and PhoeniX, a non-genetically modified method that facilitates meiotic recombination in hybrid diploid or polyploid yeast cells. These advancements enable the company to support the development of new products that address pressing global food and industrial challenges, expanding natural biodiversity through natural breeding techniques.